A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms
The DOI matches its Crossref record.
Abstract
Buspirone is a new antianxiety compound of a totally new type which may avoid the dependence problems of its predecessors. This study was designed to evaluate any possible cross-tolerance to the benzodiazepines. Twenty-four outpatients on long-term therapeutic dose benzodiazepine treatment, who wished to discontinue treatment, were allocated randomly to placebo substitution or buspirone substitution and then withdrawal over a total of 10 weeks. Assessments were made at weekly intervals. Of the 24 patients entered into the trial, 13 received buspirone and 11 placebo. Only five of the buspirone and six of the placebo patients successfully completed withdrawal. Some anxiolytic action of buspirone was detected, but it was insufficient to materially assist the withdrawal. No evidence was found that buspirone was cross-tolerant to the benzodiazepines. It was concluded that buspirone does not help benzodiazepine withdrawal and does not suppress benzodiazepine withdrawal symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While the combined evidence suggested a slight benefit for buspirone on the outcome of BZD discontinuation”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [114]
In the citing paper
“A total of six studies compared buspirone to placebo to support the tapering process in adults.113–118”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [114]
Citations
Cites
Still being checked.
Cited by
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Rickels, K. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290060008 · Cited by 384
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[75] Although initially regardconducted in the US, and one in France.[43-50] Many ed as a ‘pure’ antagonist, subsequent work in both other studies were excluded for a variety of reasons, animals and humans has suggested that flumazenil is including inappropriate outcome measures, setting a mixed agonist/antagonist, de…”
BackgroundResultSelf-citationBuspirone: What is it all about?
Loane, C., & Politis, M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.04.032 · Cited by 222
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Metadata
- Authors
- LADER, M., & OLAJIDE, D.
- Affiliations
- University of London (GB)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1987-02
- Volume
- 7
- Issue
- 1
- Pages
- 11???15
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1996454411
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2013: 1 · 2012: 2
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- buspirone, benzodiazepine withdrawal, cross-tolerance, benzodiazepine dependence, anxiolytics, benzodiazepine discontinuation, placebo comparison
- MeSH terms
- Adult, Benzodiazepines, Buspirone, Clinical Trials as Topic, Drug Tolerance, Female, Humans, Male, Middle Aged, Pyrimidines, Substance Withdrawal Syndrome, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms. https://app.cochat.ai/papers/10.1097/00004714-198702000-00003
- The paper
- LADER, M., & OLAJIDE, D. (1987). A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198702000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.